The Psychosocial Burden of Psoriasis

Kimball, Alexa B.; Jacobson, Christine C.; Weiß, Stefan; Vreeland, Mary Glenn; Wu, Ying

doi:10.2165/00128071-200506060-00005

Cited by 471 publications

(418 citation statements)

References 71 publications

Supporting

Mentioning

384

Contrasting

Unclassified

Order By: Relevance

“…In addition, these negative feelings are likely to be due to the impaired psychological status, stigmatization and feeling embarrassed because of the appearance of skin lesions in public. Also the result of some studies have shown that psoriasis can cause psychological problems due to stigmatization, depression, anxiety and social problems which support our findings mentioned above (16,(25)(26)(27). In our study, results suggested that RP and RE scales have a significant linear relation with patients' age.…”

Section: Discussionsupporting

confidence: 89%

Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran

et al. 2014

View full text Add to dashboard Cite

Background: Psoriasis is a chronic inflammatory disease, which decreases the health-related quality of life (HRQOL) of the affected patients. There are various determinants related to the patients' HRQOL. Objectives: The objective of this study was to assess the HRQOL of a group of Iranian psoriatic patients in comparison with healthy adults. Patients and Methods: This cross-sectional study was conducted in Shiraz, Iran. Ninety-six psoriatic patients and a control group of 200 healthy subjects were participated in the study. SF-36 questionnaire was used for the data collection. HRQOL was analyzes according to some selected variables including gender, age, education level, duration of the disease, and also in comparison with the control group. Results: Ninety six patients with psoriasis (mean SD age of 35.72 9.95) included 41 males and 55 ty females. The control group had statistically significant (P-Value < 0.001) higher scores in all 8 scales of HRQOL. Physical and emotional role limitation (RP and RP) scales were significantly different in patient group based on the age. Scores forall the 8 scales and 2 summary measures of mental and physical health increased with increasing educational level. Conclusions:The negative impact of psoriasis on various aspects of patients' QOL is an undeniable fact. The results of the present study indicate the necessity of appropriate therapeutic, social and psychological interventions in psoriasis patients in order to help them have better life quality.

show abstract

Section: Discussionsupporting

confidence: 89%

Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran

et al. 2014

View full text Add to dashboard Cite

show abstract

“…1 In addition to its cutaneous manifestations, psoriasis has been associated with arthritis, depression, and reduced quality of life. [2][3][4] Recent understanding has shown that as a systemic inflammatory condition, psoriasis is analogous to other immune disorders, such as systemic lupus erythematosus or rheumatoid arthritis. 5 Considering that these specific disorders have been associated with cardiovascular (CVD) and other vascular diseases, 6,7 investigators have focused their attention on whether CVD risk factors or CVD, per se, are increased in patients with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

et al. 2011

View full text Add to dashboard Cite

“…Psoriasis Area and Severity Index (PASI) score and Physician's Global Assessment (PGA)]. However, moderate to severe psoriasis affects patients both physically2, 3 and psychologically,3, 4, 5, 6 leading to major health‐related quality of life (HRQoL) impairment. Therefore, outcome assessments which encompass patient‐reported outcomes (PROs) as well as clinical efficacy are required in order to reflect the complete patient experience.…”

Section: Introductionmentioning

confidence: 99%

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Griffiths

Vender

Sofen

et al. 2016

Acad Dermatol Venereol

View full text Add to dashboard Cite

BackgroundTofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. A Phase 3 withdrawal/re‐treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re‐treatment was effective in patients with chronic plaque psoriasis.ObjectivesTo describe the effects of tofacitinib withdrawal/re‐treatment on health‐related quality of life (HRQoL) and disease symptoms measured by patient‐reported outcomes (PROs).MethodsThe study was divided into initial treatment, treatment withdrawal, and re‐treatment periods. Initial treatment: patients were randomized to receive tofacitinib 5 (n = 331) or 10 mg (n = 335) BID for 24 weeks. Treatment withdrawal: patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI) score from baseline and Physician's Global Assessment of ‘clear’/‘almost clear’ at Week (W)24 received placebo (withdrawal) or the previous dose (continuous treatment). Re‐treatment: at relapse (> 50% loss of W24 PASI response) or at W40, patients received their initial tofacitinib dose. PROs included: Dermatology Life Quality Index (DLQI), Itch Severity Item (ISI), Short Form‐36 (SF‐36) and Patient's Global Assessment (PtGA).ResultsAfter initial treatment with tofacitinib 5 and 10 mg BID, substantial and significant improvements were reported for mean DLQI (baseline: 12.6 and 12.6; W24: 5.1 and 2.6) and ISI (baseline: 6.7 and 6.9; W24: 2.9 and 1.6). Patients continuously treated with tofacitinib 5 and 10 mg BID maintained those improvements through Week 56 (DLQI: 3.0 and 2.1; ISI: 2.3 and 1.4). By W40, patients withdrawn from tofacitinib 5 and 10 mg BID showed worsening in DLQI (5.0 and 6.2) and ISI (3.7 and 4.0) scores; improvements were regained upon re‐treatment (W56, DLQI: 3.4 and 2.4; ISI: 2.2 and 1.6). Similar results were reported for PtGA and SF‐36.ConclusionContinuous tofacitinib treatment provided sustained improvement in HRQoL and disease symptoms. Patients randomized to treatment withdrawal lost initial improvements. Upon re‐treatment, improvements were recaptured to levels comparable to those seen with continuous treatment.

show abstract

The Psychosocial Burden of Psoriasis

Abstract: It is essential to include measures of psychosocial morbidity when assessing psoriasis severity and treatment efficacy because of the substantial role that psychosocial burden plays in patient perception of disease severity, quality of life, and disease course.

Cited by 471 publications

References 71 publications

Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran

Assessment of Health-Related Quality of Life in Patients with Psoriasis in Comparison with Normal Subjects in Shiraz Iran

Psoriasis and Vascular Disease—Risk Factors and Outcomes: A Systematic Review of the Literature

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Contact Info

Product

Resources

About